Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacology of RJV001 in Abdominoplasty Candidates
NCT04821648Phase 1Completed
- Sponsor
- Rejuven Dermaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RJV001 in submental fat (3 arms), sponsored by Rejuven Dermaceutical Co., Ltd. Primary endpoint: Local and systemic adverse events at 30 minutes. Started Apr 2021; status: completed.
02
Drugs
RJV001
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT04821648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821648.